Persistent pulmonary hypertension of the newborn. Role of nitric oxide and endothelin in pathophysiology and treatment.
Persistent pulmonary hypertension of the newborn (PPHN) results in significant morbidity and mortality in otherwise normal term infants. Safe, effective therapies for PPHN will only be possible when they can be directed toward the specific defects producing this condition. In this review, the authors discuss three different categories of mediators that may play a role in the normal transition at birth and in the pathophysiology seen in PPHN: (1) lipid mediators, (2) the peptide endothelin, and (3) the oxidant radical, nitric oxide. The potential of using the last mediator, nitric oxide, as a treatment for PPHN is under intensive investigation and is discussed in the final section.
Steinhorn
R H
RH
State University of New York at Buffalo, School of Medicine and Biomedical Sciences, USA.
Millard
S L
SL
Morin
F C
FC
D000280:Administration, Inhalation; D016232:Endothelins / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007743:Labor, Obstetric; D008055:Lipids / Q000502:physiology; D008168:Lung / Q000196:embryology; D009569:Nitric Oxide / Q000008:administration & dosage / Q000502:physiology* / Q000627:therapeutic use*; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D011247:Pregnancy; D011652:Pulmonary Circulation
D016232:Endothelins; D008055:Lipids; D009569:Nitric Oxide